205 related articles for article (PubMed ID: 23519741)
1. Secondary hematological malignancies associated with temozolomide in patients with glioma.
Momota H; Narita Y; Miyakita Y; Shibui S
Neuro Oncol; 2013 Oct; 15(10):1445-50. PubMed ID: 23519741
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.
Dixit S; Baker L; Walmsley V; Hingorani M
Anticancer Drugs; 2012 Nov; 23(10):1099-106. PubMed ID: 22850321
[TBL] [Abstract][Full Text] [Related]
5. Haematological malignancies following temozolomide treatment for paediatric high-grade glioma.
Karremann M; Krämer N; Hoffmann M; Wiese M; Beilken A; Corbacioglu S; Dilloo D; Driever PH; Scheurlen W; Kulozik A; Gielen GH; von Bueren AO; Dürken M; Kramm CM
Eur J Cancer; 2017 Aug; 81():1-8. PubMed ID: 28586748
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.
Aoki T; Arakawa Y; Ueba T; Oda M; Nishida N; Akiyama Y; Tsukahara T; Iwasaki K; Mikuni N; Miyamoto S
Neurol Med Chir (Tokyo); 2017 Jan; 57(1):17-27. PubMed ID: 27725524
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge with temozolomide in patients with recurrent gliomas.
Wick A; Pascher C; Wick W; Jauch T; Weller M; Bogdahn U; Hau P
J Neurol; 2009 May; 256(5):734-41. PubMed ID: 19240962
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
[TBL] [Abstract][Full Text] [Related]
9. Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
Momota H; Narita Y; Miyakita Y; Hosono A; Makimoto A; Shibui S
Pediatr Blood Cancer; 2010 Sep; 55(3):577-9. PubMed ID: 20658636
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Khasraw M; Bell D; Wheeler H
J Clin Neurosci; 2009 Jun; 16(6):854-5. PubMed ID: 19303779
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
12. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
13. A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma.
Kosugi K; Saito K; Takahashi W; Tokuda Y; Tomita H
World Neurosurg; 2017 May; 101():816.e11-816.e16. PubMed ID: 28288919
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
[TBL] [Abstract][Full Text] [Related]
15. Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma.
Yang P; Zhang C; Cai J; You G; Wang Y; Qiu X; Li S; Wu C; Yao K; Li W; Peng X; Zhang W; Jiang T
Oncotarget; 2016 Nov; 7(48):80091-80100. PubMed ID: 27590514
[TBL] [Abstract][Full Text] [Related]
16. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Chou KN; Lin YC; Liu MY; Chang PY
J Clin Neurosci; 2014 Apr; 21(4):701-4. PubMed ID: 24291476
[TBL] [Abstract][Full Text] [Related]
18. The outcomes of concomitant radiation plus temozolomide followed by adjuvant temozolomide for newly diagnosed high grade gliomas: the preliminary results of single center prospective study.
Shawky H; Abo Hamar AH; Galal S; Zakaria F; El-Shorbagy D
J Egypt Natl Canc Inst; 2009 Jun; 21(2):107-19. PubMed ID: 21057562
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Rizzo D; Scalzone M; Ruggiero A; Maurizi P; Attinà G; Mastrangelo S; Lazzareschi I; Ridola V; Colosimo C; Caldarelli M; Balducci M; Riccardi R
J Chemother; 2015 Feb; 27(2):106-10. PubMed ID: 25466729
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]